Sun Says Specialty Drug Spend Will Check Profit Growth
Executive Summary
Sun Pharmaceutical Industries has cautioned that investments to ramp up its specialty business will “check” profit growth near-term, as a one-off charge pushed down its fourth-quarter net income by more than 50%.